National Amyotrophic

Lateral Sclerosis (ALS) Registry

OMB Control No. 0923-0041 (Expiration Date: 5/31/2026)

Revision

Supporting Statement Part A –

Justification

Principal Investigator:

Paul Mehta, MD

Agency for Toxic Substances and Disease Registry

4770 Buford Highway, MS F-57

Atlanta, GA 30341

Phone: 770-488-0556

Fax: 770-488-1537

Email: pum4@cdc.gov

Date: June 6, 2024

Table of Contents

[A.1. Circumstances Making the Collection of Information Necessary 3](#_Toc121936937)

[A.2. Purpose and Use of the Information Collection 7](#_Toc121936938)

[A.3. Use of Improved Information Technology and Burden Reduction 9](#_Toc121936939)

[A.4. Efforts to Identify Duplication and Use of Similar Information 9](#_Toc121936940)

[A.5. Impact on Small Businesses or Other Small Entities 10](#_Toc121936941)

[A.6. Consequences of Collecting the Information Less Frequently 10](#_Toc121936942)

[A.7. Special Circumstances Relating to the Guidelines of 5 CFR 1320.5 10](#_Toc121936943)

[A.8. Comments in Response to the Federal Register Notice and Efforts to Consult Outside the Agency 10](#_Toc121936944)

[A.9. Explanation of Any Payment or Gift to Respondents 14](#_Toc121936945)

[A.10. Protection of the Privacy and Confidentiality of Information Provided by Respondents 14](#_Toc121936946)

[A.11. Institutional Review Board (IRB) and Justification for Sensitive Questions 18](#_Toc121936947)

[A.12. Estimates of Annualized Burden Hours and Costs 19](#_Toc121936948)

[A.13. Estimates of Other Total Annual Cost Burden to Respondents and Record Keepers 23](#_Toc121936949)

[A.14. Annualized Cost to the Federal Government 23](#_Toc121936950)

[A.15. Explanation for Program Changes or Adjustments 24](#_Toc121936951)

[A.16. Plans for Tabulation and Publication and Project Time Schedule 25](#_Toc121936952)

[A.17. Reason(s) Display of OMB Expiration Date is Inappropriate 26](#_Toc121936953)

[A.18. Exceptions to Certification for Paperwork Reduction Act Submissions 26](#_Toc121936954)

[References 26](#_Toc121936955)

Part A. Justification

**Goal of the study:** As mandated by Congress, the goal of this study is to continue collecting data, with revision, for the National Amyotrophic Lateral Sclerosis (ALS) Registry to better describe the incidence and prevalence of ALS and to identify risk factors for the disease.

**Intended use of the resulting data:** The National ALS Registry allows estimates of ALS prevalence as well as risk factors. ATSDR endeavors to improve the completeness, representativeness, and accuracy of the Registry data over time.

**Methods to be used to collect:** Self-reports by persons with ALS (PALS), registry data requests from researchers, and progress reports from ALS service organizations. ATSDR currently identifies additional cases from three large national administrative databases (Medicare, Veterans Health Administration, and Veterans Benefits Administration). ATSDR proposes to add more complete ALS case ascertainment reporting from up to six state ALS registries and non-profit ALS organizations.

**Subpopulation to be studied:** US citizens and legal residents with ALS

**How data will be analyzed**: Descriptive statistics of PALS including number of people identified, number of individuals who self-identified vs. those obtained from existing data, mean age, sex distribution, racial distribution, geographic distribution by region, and distribution of other characteristics such as cigarette use, alcohol use, occupation, service in the military, physical activity, and family history.

# A.1. Circumstances Making the Collection of Information Necessary

This is a request to continue the National Amyotrophic Lateral Sclerosis (ALS) Registry (OMB Control No. 0923-0041, expiration date 05/31/2026), with a non-substantive change request for two additional modifications.

The Agency for Toxic Substances and Disease Registry (ATSDR) is authorized by the Public Law No. 110-373, the ALS Registry Act (**Attachment 1**), to: (1) develop a system to collect data on amyotrophic lateral sclerosis (ALS) and other motor neuron disorders that can be confused with ALS, misdiagnosed as ALS, or progress to ALS; and (2) establish a national registry for the collection and storage of such data to develop a population-based registry of cases.

The National ALS Registry uses a two-pronged approach to identify prevalent cases of ALS in the United States. The first approach used to identify prevalent cases relies on existing administrative data (from the Centers for Medicare and Medicaid Services, the Veterans Heath Administration [VHA], and the Veterans Benefits Administration [VBA]). A pilot tested algorithm is applied to the administrative data that identifies persons with ALS on the basis of encounter codes such as having ALS listed as a code in the visit record or having such a code and having seen a neurologist, a death certificate listing ALS as a cause or contributing cause of death, and prescription for Riluzole.1 The second approach, which was launched to the public on October 19, 2010, uses a secure web portal (https://www.cdc. gov/als) to identify cases that are not included in the national administrative databases. This approach allows patients to self-identify and enroll in the National ALS Registry if screening criteria are met. An additional advantage of this approach is those who self-enroll in the Registry can take brief surveys that are used to evaluate possible risk factors for ALS (e.g. genetics and environmental and occupational exposures).2

In the last three years, the National ALS Registry has had several major accomplishments. In April 2022, the sixth annual estimate of ALS prevalence for the entire United States was published in the Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration journal (ALS FTD).2 The analysis shows that during January 1-December 31, 2017, a total of 17,800 persons meeting the surveillance case definition of definite ALS were identified by the Registry, for a prevalence of 5.5 cases of ALS per 100,000 persons in the U.S. general population. In addition to the Registry’s current data sources, the capture-recapture methodology was applied to this report. Capture-recapture is a well-established statistical methodology used to estimate the percentage of missing cases. Using this methodology, 24,821 additional ALS cases (prevalence of 7.7 per 100,000) were identified, leading to a total of 31,843 cases of ALS (prevalence of 9.9 per 100,000) in the United States in 2017. Additionally, the National ALS Registry published an incidence report for ALS cases from 2014-2016 in the Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration journal (ALS FTD).3 This analysis identified 5,695 incident ALS cases in 2014, 6,045 ALS cases in 2015, and 4,861 cases of ALS in 2016. Age- adjusted incidence rates were calculated by year for 1.7 per 100,000 for 2014, 1.5 per 100,000 for 2015, and 1.5 per 100,000 for 2016. The recently published incidence report helps to describe ALS across the United States and adds to the previously published findings for ALS incidence in smaller defined geographic areas of the United States. 4-9

Since the inception of the Registry, the pattern of characteristics (e.g., age, sex, and race/ethnicity) among persons with ALS have remained unchanged. Overall, ALS was more common among whites, males, and persons aged 60–69 years. The age groups with the lowest number of ALS cases were persons aged 18–39 years and those aged ≥80 years. Males had a higher prevalence rate of ALS than females overall and across all data sources. These findings remained consistent during October 2010–December 2017.2 Per the terms of clearance, the ALS FTD prevalence report includes a list of limitations covering the possible under ascertainment of cases, potential errors in de-deduplicating files or data, and the inability to match cases from private insurances. More details about the findings and limitations published can be found in Supporting Statement Part B, Section B.1.

Data from and about the National ALS Registry has been presented annually at the American Academy of Neurology meeting, the Northeastern ALS Consortium meeting, and the International Symposium on ALS/motor neuron disease (MND). Persons enrolled in the National ALS Registry can opt to receive emails about research studies for which they may be eligible. As of August 2022, approximately 400,000 emails have been sent for 68 studies over the last nine years.

After 11 years of recruitment and self-registration in this system, approximately 1,500 ALS cases enroll each year. The existing Veterans Health Administration, Veterans Benefits Administration, Medicare, and Medicaid data remained remarkably consistent over a 10-year time period, from 2001-2009, related to the distribution of age (~60%, 60-79 years of age at diagnosis), race (~87% white), and sex (~57% males).

In comparison with those cases identified through the national databases, we find that those individuals who self-registered from October 19, 2010 – December 31, 2015, were more likely to be white (95%) and slightly younger (53%, less than 60 years of age at diagnosis). There was no difference in sex among those identified through national databases compared with those who self-registered (~60% male). The difference in the demographics of those who self-register compared with those in the national databases suggests that the self-registration portion of the National ALS Registry is working to identify individuals that would have been missed if only existing databases had been used. The differences in the racial and age distributions could be attributed to access and familiarity with web-based technology and computers. To date, more than 18,000 persons with ALS (PALS) have registered and 58% have taken at least one survey. Although this varies by year, in CY2021, 931 persons with ALS self-registered and approximately 53% took at least one survey.

In January 2017, the National ALS Biorepository (Biorepository) was launched. The Biorepository is novel in several ways. First, it obtains samples from Registry enrollees via in-home collection (e.g., blood, hair, or saliva) and postmortem collection (e.g., brain, bone, spinal cord, cerebrospinal fluid, muscle, and skin) at no charge to patients or their caregivers. Second, specimens from the National ALS Biorepository are collected from a geographically representative sample of Registry enrollees. The sample of persons recruited to participate in the Biorepository correlates with the population distribution of the United States and each year will include at least one person from each state. Third, these deidentified samples are paired with completed risk factor survey data (e.g., occupational and military history) from the Registry. Researchers are currently able to request samples alone or paired with risk factor data. The availability of additional specimens from a national sample of ALS patients further expands research potential on the genetics, potential biomarkers, environmental pollutants, and etiology for ALS. The Biorepository has received samples from 1,495 persons with ALS and provided approximately 12,091 samples to 22 different ongoing projects through the end of July 2022.

The National ALS Registry collaborates with partner organizations (Les Turner, MDA and the ALS Association) to increase awareness of the Registry. They distribute the information through a variety of methods including group activities such as support groups, clinics, ALS seminars, and fundraising events ( e.g. walk, golf tournaments). In addition to activities, the partner organizations also utilize social media messaging and local mailings (e.g., tweet, email blast, newsletter) to disseminate information to increase awareness of the Registry.

This is a nonmaterial/non-substantive change request for the National ALS Registry. The modifications listed in Section A.15 are minor updates to strengthen the usefulness of the National ALS Registry for researchers and participants. The proposed changes have been submitted and approved by the CDC/ATSDR IRB.

# A.2. Purpose and Use of the Information Collection

The objective of this information collection request (ICR), theNational ALS Registry, is to continue a population-based surveillance system/registry for ALS. First approved in 2010 for self-registration, the primary goal of the surveillance system/registry remains to obtain reliable information on the incidence and prevalence of ALS and to better describe the demographic characteristics (age, race, sex, and geographic location) of PALS. Those interested in participating in the National ALS Registry must answer a series of validation questions (**Appendix B**) and if determined to be eligible they can register (**Appendix C**).

The secondary goal of the surveillance system/registry is to collect additional information on potential risk factors for ALS, including, but not limited to, family history of ALS, smoking history, and military service. In 2013, this ICR was approved to collect 10 additional risk factor surveys covering residential history, life-time occupational exposure, home pesticide use, hobbies, hormonal and reproductive history (women only), caffeine use, trauma, health insurance, open-ended supplemental questions, and clinical signs and symptoms. The data collected will be used to describe the characteristics of the ALS Registry participants. Data can also be used to generate hypotheses which could become the subject of research studies.

In 2016, a biorepository component was added to increase the value of the National ALS Registry to researchers. As part of registration, the participant can request additional information about the biorepository and provide additional contact information (**Appendix C**). The sample of persons recruited to participate in the Biorepository correlates with the population distribution of the United States and each year will include at least one person from each state. These de-identified samples are paired with completed risk factor survey data (e.g., occupational and military history) from the Registry. Researchers are currently able to request samples alone or paired with risk factor data. There are three types of specimen collections, in-home, saliva only, and postmortem. The following table outlines the types of specimens collected in the home and their potential use:

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Collectionpriority | Sample preservative | # tubes | ml /tube | Fractions | Examples of specimen use |
| Blood |
|  1 | K2EDTA | 1 | 10 | White cells (buffy coat), red cells, plasma | DNA, proteins, red blood cell lipids  |
|  2 | K2EDTA  | 1 | 6 | Whole blood  | Lead and other metals |
|  3 | Plain, (no anticoagulant | 1 | 10 | Serum  | Clinical biochemistries, metabolic products, other small molecules |
|  5 | PAXgene RNA | 2 | 5  | RNA-stabilized whole blood | Intracellular RNA |
|  |
| Urine | 9 | -- | Electrolytes, environmental chemicals, metabolic products |
| Saliva (Oragene Collection Kit) | 2 | -- | DNA |

The brain, spinal cord, cerebral spinal fluid (CSF), muscle, and bone and small skin samples (to isolate primary fibroblasts) will be collected postmortem from up to 40 cases. The procedures and methods used in the biorepository pilot study can be found in **Attachment 7**. After the pilot study was completed, its protocol was formally added to the ALS Registry research protocol as **Appendix S**.

In addition to fulfilling the two-part Congressional mandate, the Registry is designed to be a tool for ALS researchers. Now that the Registry has matured, ATSDR will make data and specimens available to approved researchers. Information about the sampling scheme can be found in Supporting Statement Part B, Section B.1. In addition, ATSDR is also collaborating with ALS service organizations to conduct outreach activities through their local chapters and districts as well as on a national level. ATSDR will collect summary information on their outreach efforts in support of the Registry (Section A15) ATSDR will use the information in comparison with the number of PALS self-registering to evaluate how effective the outreach activities are at increasing enrollment in the Registry and completing the survey modules.

# A.3. Use of Improved Information Technology and Burden Reduction

This collection of information will be done using electronic techniques in lieu of paper reporting forms. Screen shots of the validation questions, registration page, and voluntary surveys can be found in **Appendices B and C**. Updated screenshots for the revised survey modules in **Appendix E** will be provided as a non-substantive change request after OMB approves this revision ICR. Once registered, cases will have the opportunity to participate in questionnaires on risk factors. The registration instrument requires collection of only the minimum information necessary for the purposes of the registry system.

# A.4. Efforts to Identify Duplication and Use of Similar Information

This data collection originated as a result of several ATSDR meetings between the stakeholders including scientists, neurologists, advocacy groups, and ethicists in 2009. In 2010, ATSDR developed a proposal to build on work that had already been done and coordinate the extant groups and create a larger database, rather than duplicate effort. The proposal outlined a strategy for identifying people using administrative databases such as Medicare, Medicaid, the Veterans Administration, and health insurance databases, and then to build on that data. ATSDR holds annual meetings with stakeholders to discuss the Registry and get input into future directions.

Because ATSDR staff is in communication with The Council of State and Territorial Epidemiologists, advocacy groups, and ALS researchers, it is clear that no nationwide collection exists for this field of study. The literature describes a number of research studies on hospital or physician-based cases, but there is no prior history of a national registry. Communications with experts in ALS did not bring to light any similar data collection efforts.

No other collective registry exists that tracks ALS nationwide.

# A.5. Impact on Small Businesses or Other Small Entities

This data collection will not involve small businesses.

# A.6. Consequences of Collecting the Information Less Frequently

The average life expectancy for an individual after diagnosis with ALS is 2-3 years. It is necessary to allow individuals to register as soon as they are diagnosed. Without prompt registration individuals may become too ill or die before participating.

There are no technical or legal obstacles to reducing burden.

# A.7. Special Circumstances Relating to the Guidelines of 5 CFR 1320.5

There are no special circumstances associated with this data collection.

# A.8. Comments in Response to the Federal Register Notice and Efforts to Consult Outside the Agency

1. The 60-day Federal Register Notice was published in the *Federal Register* on September 30, 2022 (**Attachment 2**). One comment was received during the 60-day Federal Register Notice (**Attachment2a**). ATSDR has reviewed the comment and will consider proposing an incentives pilot project to OMB in the future.
2. The following individuals were consulted to obtain their views on the availability of data, the clarity of instructions, disclosure, and on the data elements to be recorded and reported. ATSDR holds annual meetings with stakeholders in Atlanta, Georgia. The last annual meeting was held on August 29-30, 2023.

Abdul Ally, BS

Area Director

Laboratory Science and Operations

Fisher BioServices

James Berry, MD, MPH (NEALS)

Neurology

Marianna Bledsoe, MA

Independent Research Consultant

Adjunct Assistant Professor

George Washington University

Kevin Boylan, MD (ALSRG)

Director, ALS Center

Department of Neurology

Mayo Clinic

Walter Bradley, DM

Professor and Chairman Emeritus

University of Miami Miller School of Medicine

Benjamin Rix Brooks, MD, Director

Carolinas Neuromuscular/ALS Center

Department of Neurology

Carolinas Medical Center

Lucie Bruijn, PhD

Science Director and Vice President

ALS Association

Ben Buehrer, PhD

Vice President and CSO

ZenBio

Roderick A. Corriveau, Ph.D.

Program Director, Neurodegeneration

NIH/NINDS

Valerie Cwik, MD

Medical Director

Muscular Dystrophy Association

Stevan Gibson, Vice President

Government Relations & Public Affairs

ALS Association

Amelie K. Gubitz, PhD

Program Director, Neurodegeneration

National Institute of Neurological Disorders and Stroke

National Institutes of Health

Elaine Gunter, MT(ASCP)

Specimen Solutions, LLC

Ted Harrata

Patient Advocate/National Trustee

ALS Association, Georgia Chapter

Scott Hixon

Technical Director

Fisher BioServices

Edward Kasarskis, MD, PhD

Co-Principal Investigator, VA Neurolog

VA ALS Registry

Wendy Kaye, PhD

Senior Epidemiologist

McKing Consulting Corporation

Rebecca Kidd

Patient Advocate

Lorene Nelson, PhD

Associate Profession

Division of Epidemiology

Department of Health Research & Policy

Standford University School of Medicine

Yaffa Rubinstein, PhD

Director of Patient Resources for Clinical and Translational Research

Office of Rare Diseases Research

National Center for Advancing Translational Sciences (NCATS)

National Institutes of Health

James Sejvar, MD

Neuroepidemiologist

National Center for Emerging and Zoonotic Infectious Diseases

Eric Sorenson, MD

Neurologist

Mayo Clinic

Thor Stein, MD, PhD

Assistant Professor of Pathology

Boston University School of Medicine

Jeffrey Thomas

Vice Pres. Sourcing & Donor Services

The National Disease Research Interchange (NDRI)

David Thurman, MD

Centers for Disease Control & Prevention

Bryan Traynor, MD

Investigator

National Institute on Aging

Stephen Van Den Eeden, PhD

Senior Epidemiologist, Div. of Research

Kaiser Permanente Northern California

Marc Weisskopff, PhD, ScD

Associate Professor of Environmental and Occupational Epidemiology

Harvard University

Patrick Wildman, Director

Communications & Public Policy

ALS Association

# A.9. Explanation of Any Payment or Gift to Respondents

Participants will not receive any token of appreciation for their participation.

As a part of the Incentives Pilot project, participants who enroll in the state of Texas through one of the ALS Association Chapter clinics will qualify for monetary incentive through electronic gift cards. The participant will receive $50 for enrolling in the National ALS Registry and second $100 for completing all applicable 18 risk factor surveys. Both rewards will be distributed separately, upon completion of the task. This incentive only applies to those participating in the Texas pilot project and not to all of those who enroll in the Registry. This incentive will only be offered during the 6-9 month program using funds allocated to the ALS Association.

# A.10. Protection of the Privacy and Confidentiality of Information Provided by Respondents

This submission has been reviewed by the CDC Chief Privacy Officer who determined that the Privacy Act does apply **(Attachment 5)**. The applicable Systems of Records Notice is 09-19-0001, *Records of Persons Exposed or Potentially Exposed to Hazardous or Toxic Substances.* The information in identifiable form (IIF) categories and the system are discussed below.

Additionally, the NCEH/ATSDR Information Systems Security Officer (ISSO) has verified that a full system privacy impact assessment (PIA) from the CDC Cybersecurity Program Office (CSPO) is up to date **(Attachment 5)**. ATSDR completes annual Certification & Accreditation for the web portal**.**

Data security is of paramount importance and technical, physical, and administrative safeguards are outlined below.

The ALS registry allows for web-based collection of data on PALS. The registry is directed to all PALS. Most PALS are diagnosed between the ages of 55 and 75 and cases are rarely diagnosed below the age of 30 years of age. Others who can register are family members of affected persons or researchers. Once a PAL is registered, he/she can voluntarily participate in on-line surveys of risk-factors for ALS, as described in Section A2. Data collection is organized in a modular format that is designed to decrease the fatigue burden on participants and can be expanded as additional scientific information becomes available.

The primary goal of the registry is to provide accurate estimates of incidence and prevalence which cannot be done without removing duplicate entries. The National ALS Registry is a combination of individuals identified through existing datasets and self-registration. The administrative data sets, Medicare, Medicaid, Veterans Health Administration, and Veterans Benefits Administration use SSN as a unique identifier. It will be necessary to use the last five digits of the SSN to make sure that there are no duplicates in the ALS Registry. This is true for eliminating duplicates between the VA data and the Medicare data, for example, and adding the individuals self-identified via the web portal. Name alone is not sufficient to remove duplicates. This information is necessary because case information will be collected from a number of sources, and it is imperative that duplicates be identified and consolidated. The primary goal of the registry is to provide accurate estimates of incidence and prevalence which cannot be done without removing duplicate entries.

Although information about disease is needed to verify eligibility, the individual responses other than date of diagnosis will not be stored.

Individuals who register will create an account with a password and security questions. Account name and password will be necessary to access the account.

External Users (ALS Patients/External Researchers) must self-register before accessing the ALS Web Portal. IIF is collected during this registration process (full name, email address, city and state, last 5 digits of the Social Security Number [SSN], month and year of birth) and users are allowed to create their own unique username and password. Users are also required to answer security questions which are used as alternative authentication credentials if their password is forgotten. Upon successful registration, users are systematically logged into their accounts. External Users are authenticated against a backend Structured Query Language (SQL) encrypted database.

As the number of studies related to ALS increases, it is increasingly important to be able to pool data across studies and biorepositories. The National Institutes of Health (NIH) has led the way in developing the Global Unique Identifier (GUID) <https://ncats.nih.gov/grdr/guid> which allows the creation of a unique identifier so that data and samples can be shared and linked without sharing IIF. This is especially important when using samples from multiple sources because persons with ALS may be in more than one biorepository. During registration we will ask Registry participants if they want to have a GUID added to their records, and if so, they will be asked to provide the information necessary to generate the GUID (**Appendix C**).

Internal Users (CDC Employees/System Administrators) are required to be pre-approved by ATSDR management before accessing the ALS Intranet Web Portal. Once a user is approved, ATSDR management sends a request to the System Administrator to create a user account. The request must include the user’s CDC User ID, First Name, Last Name, Gender, City, State, Country, and Email in order for the System Administrator to add the user to the ALS System. Users must first log into the CDC network to access the ALS Intranet Web Portal and are authenticated using Active Directory. No login is required.

The ALS system creates a sequential unique identifier in the database every time a user account is created. This unique identifier identifies each user and is used to link user information inside the system. Another unique identifier (Last 5 digits of SSN) will be used to verify patient data outside of the ALS system.

The information required for registration has been limited to only that needed to make sure that an individual truly has ALS and is not already part of the registry. Address information has been limited to city and state, and email address; birth information has been limited to month and year of birth, and only the last five digits of the SSN will be collected. For authentication purposes, users will be verified using their unique username along with their password. External Users are allowed to self-register online and create their own username. Duplicate checks are implemented during registration to ensure uniqueness of usernames and emails.

External users are allowed to change or reset their passwords but are not allowed to retrieve their password. Passwords can be changed via the user’s account after the user has been authenticated by providing the old password and can only be changed once every 6 days. If a user forgets his/her password, the password can be reset by providing alternate authentication credentials. These credentials include the user’s username, registered email address, and a security question. Passwords are required to be reset every 180 days. Users will be given a 2 week email notice before their password expires. Users will be directed to reset their expired password if they attempt to login after their password has expired.

Usernames are unique and cannot be changed. Users must contact the System Administrator by phone or email to retrieve their username. The System Administrator is required to ask verification questions before releasing any information to the user; which can include the user’s First and Last Name, Month & Year of Birth, City, State, and two security questions.

The status of an account will change to inactive if the user has not logged into his/her account in 6 or more months. Users will be given a 2-week email notice before their account is inactivated. Users will be required to contact the System Administrator by phone to re-activate their account. The System Administrator will be required to verify the user by asking verification questions which include the user’s First and Last Name, Date of Birth: Month & Year (ALS Patients only), Address: City, Province/State, Country, and 2 security questions.

No personal information or credentials can be sent to a user’s email, only notices or confirmations.

User accounts cannot be removed and remain in the database permanently. Only the account status can change.

IIF fields will be masked on the Graphical User Interface because of the sensitivity of the data. For example, month and year of birth will be masked.

All IIF which includes the last 5 digits of the SSN will be encrypted using AES\_256 (Advance Encryption Standard 256 bit) encryption, the strongest encryption standard supported by SQL Server 2008.

To encrypt/decrypt data in database columns designed to hold IIF, a user must be given access to open and close a symmetric key.

Production and test servers are stored in a server room secured by the CDC. Access tools are in place to secure entry into CDC buildings (Guards, ID Badges, Key Card, Cipher Locks, and Closed Circuit TV).

Once an account is created or a survey module completed, this information will be removed from the web-based system to a secure server without Internet access.

ATSDR will merge the self-identified PALS into the registry after first checking for duplicates. The registry will be maintained on a secure server or stand-alone hard drive. Access to the data will be limited to approved study personnel. De-identified data sets will be used for data analysis.

There will be an opportunity for respondent consent. A screen providing the Privacy Act Statement will appear prior to the registration screen on the website (**Appendix F**). A copy of the consent document is included (**Appendix D1**) outlining the intended uses of the information collection and that there are no plans for identifiable data sharing other than with ATSDR staff and contractors working on the ALS Registry. De-identified data will be shared and we are working with agency representatives to comply with the Open Data Policy requirements.

Researchers may request data from the National ALS Registry and/or samples from the Biorepository. Before release of any data, researchers must attest that they will not attempt to re-identify the data. Data that are only from the administrative datasets will not be released. Data are coded and files do not contain PII. Each data request is reviewed to evaluate the possibility that specific data elements or elements in combination could be potentially identifying and whether or not creating categories for a specific variable, e.g., age, would decrease this potential identifiability. If there is a potential for identification and categorization would eliminate the possibility, we will include the categorical data instead of individual values. If there is a potential for identification and categorization would eliminate the possibility, we will include the categorical data instead of individual values. In other cases, variables may be totally eliminated. One staff member will be responsible for creating the requested data set with the agreed upon variables adjusted as needed. A second staff member will review the file to reassess the potential for identifiability and make adjustments before any data are sent.

Any of the survey data may be requested matched to the biospecimens. However, any data requests would need to undergo the same non-disclosure review described above. In addition, we will provide a minimal dataset requested by ALS experts that includes the following if available, age at diagnosis, age at symptom onset, age at death, sex, race, state of residence at registration, survival time, immediate relative with ALS (yes/no), immediate relative with Alzheimer’s disease or Parkinson’s disease (yes/no), location of symptom onset (e.g., hand, swallowing), and ALS Functional Rating score closest to the specimen collection.

# A.11. Institutional Review Board (IRB) and Justification for Sensitive Questions

CDC/ATSDR IRB approval for the ALS Registry protocol was originally obtained on 10/26/09 and the most recent annual continuation was approved on 10/18/24 (**Attachment 4**). The IRB approved a waiver of documentation of consent for the registration and on-line surveys. The consent form as it appears online is in **Appendix D1**.

IRB approval of adding a biorepository component was received on 2/12/16. Because there will be direct interactions with those who take part in the biorepository and the need to store samples for future study, there are separate consent forms requiring signatures. The biorepository component has three consent forms for in-home collection of biological specimens (**Appendix D2**), postmortem collection of tissues including brain and spinal cord (**Appendix D3**), and saliva only collection (**Appendix D4**). Saliva only collections were added to increase the number of PALS who could participate in the biorepository if additional money becomes available at the end of fiscal years.

Registration questions that might be considered sensitive by a portion of the general population include full name, month and year of birth, last five digits of the Social Security numbers,[[1]](#footnote-3) and self-verification of diagnosis of ALS. Epidemiologic characteristics such as sex and geographic location are routinely collected because of their significance in describing effected populations and evaluating resource allocation.

One variable necessary to calculate the Global Unique Identifier (GUID) is sex at birth. This might be considered sensitive by those who have had a sex change. This information is not permanently stored. This information is only kept long enough to generate the GUID and validate the number and then it is wiped from the system. Those who do not want to provide that information can decide not to participate in the GUID process.

The incentives pilot project and the consent form modification have both been reviewed and approved by the CDC/ATSDR IRB on 05/08/24. The documents that have been modified and approved include the National ALS Registry protocol, Appendix D (consent form), and Appendix U (Incentive Pilot Proposal) and U2 (Sign up form).

# A.12. Estimates of Annualized Burden Hours and Costs

Burden hours are included in Table 1 and represents a decrease in burden from the previously approved 1,945 to 1,757 hours, a net decrease of 188 hours.

Based on past Registry experience, it is assumed that approximately 90 percent of persons to be screened (n=1,670) will yield 1,500 individuals successfully registered each year. The initial screening questions which determine eligibility are expected to take 2 minutes and registration to take 10 minutes.

Registered individuals will have the opportunity to complete short one-time surveys related to risk factors for ALS and demographic characteristics. Previously, there were 17 such five-minute surveys. The 17 modules are now reorganized into the Essential Questionnaire and one of the four Follow-up Question modules: 1) Demography, 2) Lifestyle Information, 3) Environmental Factors, and 4) ALS-associated Clinical Factors. The time burden per respondent for each of the new surveys now ranges from two to 32 minutes.

The five-minute disease progression survey requirements remain unchanged. In Year 1 for new registrants, the disease progression survey will be administered at 0 (baseline) months after the Essential Questionnaire is completed, and then at 3 months and at 6 months. In Years 2 and 3, they are asked to repeat the disease progression survey on their anniversary date and at 6 months. Therefore, over three years, new registrants are requested to complete the survey seven times. For time burden estimation, the number of responses is rounded up to 3 times per year.

Those who participate in the in-home portion of the biorepository will spend approximately 30 minutes having specimens collected and answering a few questions needed to process the specimens (**Appendix S.A-1**). We estimate that 350 participants per year will spend approximately 10 minutes to collect a just saliva sample for the biorepository (**Appendix S.A-2**). In all, we are requesting 1,590 burden hours for PALS.

Researchers will be able to request epidemiological data collected by the National ALS Registry as well as the specimens collected by the biorepository. In order to assure the appropriate use of data and specimens, researchers much complete an application form and provide documentation of IRB approval and institutional support. Completion of the National ALS Registry Research Application Form (**Appendix M1)** and record gathering should take approximately 30 minutes. Those who receive data and/or specimens much provide an update on a yearly basis along with documentation of continued IRB approval. Completion of the Annual Update Form (**Appendix M2)** and record gathering should take approximately 15 minutes. In all, we are requesting 24 burden hours for researchers.

ATSDR is also collaborating with ALS service organizations to conduct outreach activities through their local chapters and districts as well as on a national level. They provide ATSDR with information on their outreach efforts in support of the Registry on a monthly basis (**Attachment 6A and 6B**). In all, we are requesting 143 burden hours for service organizations.

For this non-substantive change request, the program is adding a short sign-up form for the Incentives Pilot Project (**Appendix U2**). As Texas is currently and historically has been an under-enrolling state, the estimated number of burden hours have not been reached for this state. Because national projections are not being met for enrollment and survey completion, this strategy will be implemented in hopes to increase Registry enrollment and risk factor survey completion. This form will not change any burden hours (OMB), as we are not currently meeting our anticipated enrollment and hope this monetary incentive promotes enrollment and awareness of the Registry. This form will only be used by the Texas Chapter of the ALS Association in outreach efforts through their clinics and chapters. The purpose of this form is to keep record of those who have enrolled in the National ALS Registry through the Incentive Pilot Project in the state of Texas. This form will only be used for the 6–9-month project period for this pilot and will not apply to any other states. The process to enroll in the National ALS Registry and complete risk factor surveys will remain the same for those in Texas and the United States.

Table 1: ESTIMATE OF ANNUALIZED BURDEN HOURS

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Type of Respondents | Form Name | No. ofRespondents | No. ofResponses per Respondent | Average Burden per Response (in hours) | Total Burden(in hours) |
| Persons with ALS | ALS Case Validation Questions  | 1,670 | 1 | 2/60 | 56 |
| ALS Case Registration Form | 1,500 | 1 | 10/60 | 250 |
| Essential Questionnaire | 750 | 1 | 6/60 | 75 |
| Disease Progression Survey\* | 750 | 3 | 5/60 | 188 |
| Follow-up Questions - Demography | 750 | 1 | 2/60 | 25 |
| Follow-up Questions - Lifestyle Information | 750 | 1 | 32/60 | 400 |
| Follow-up Questions - Environmental Factors | 750 | 1 | 23/60 | 288 |
| Follow-up Questions - ALS-associated and Clinical Factors | 750 | 1 | 7/60 | 88 |
| ALS Biorepository Specimen Processing Form and In-Home Collection | 325 | 1 | 30/60 | 162 |
| ALS Biorepository Saliva Collection | 350 | 1 | 10/60 | 58 |
|  | Incentives Pilot Project Sign Up form – Only for Texas Registrants\*\* | 100 | 1 | 3/60 | 5 |
| Researchers | ALS Registry Research Application Form | 36 | 1 | 30/60 | 18 |
| Annual Update | 24 | 1 | 15/60 | 6 |
| ALS Service Organizations | Chapter/District Outreach Reporting Form | 135 | 12 | 5/60 | 135 |
| National Office Outreach Reporting Form | 2 | 12 | 20/60 | 8 |
| Total |  |  |  |  | 1,762 |

\* The disease progression survey is taken initially and then 2 additional times the first year (0, 3, 6 months). Because some people’s disease progresses more rapidly, clinicians recommended adding the survey at 3 months to make sure everyone had the opportunity to take the survey a second time. In years 2 and 3, the survey would be taken at the yearly anniversary and at 6 months. For purposes of burden estimation, the number of annual responses has been rounded up to 3 times (ALSFRS Module only).

\*\*The Incentives Pilot Sign Up form only applies to the registrants of the pilot project in the state of Texas during the 6–9-month project period.

Burden costs are included in Table 2. The ALS patients and ALS service organization staff are assumed to be members of the general public and the researchers are expected to be neurologists. The mean hourly wage rate of $28.01 for ALS patients and ALS service organization staff and $128.68 for researchers is based on the US Department of Labor, Bureau of Labor Statistics May 2021 National Occupational Employment and Wage <http://www.bls.gov/oes/current/oes_nat.htm#29-0000>.

Table 2: ESTIMATE OF ANNUALIZED BURDEN COSTS

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Type of Respondents | Form Name | No. ofRespondents | No. ofResponses per Respondent | Average Burden per Response (in hours) | Hourly Wage Rate | Total BurdenCosts |
| Persons with ALS | ALS Case Validation Questions  | 1,670 | 1 | 2/60 | $28.01 | $1,559.22 |
| ALS Case Registration Form | 1,500 | 1 | 10/60 | $28.01 | $7,002.50 |
| Essential Questionnaire | 750 | 1 | 6/60 | $28.01 | $2,100.75 |
| Disease Progression Survey | 750 | 3 | 5/60 | $28.01 | $5,251.88 |
| Follow-up Questions - Demography | 750 | 1 | 2/60 | $28.01 | $700.25 |
| Follow-up Questions - Lifestyle Information | 750 | 1 | 32/60 | $28.01 | $11,204.00 |
| Follow-up Questions - Environmental Factors | 750 | 1 | 23/60 | $28.01 | $8,052.88 |
| Follow-up Questions - ALS-associated and Clinical Factors | 750 | 1 | 7/60 | $28.01 | $2,450.88 |
| ALS Biorepository Specimen Processing Form and In-Home Collection | 325 | 1 | 30/60 | $28.01 | $4,551.63 |
| ALS Biorepository Saliva Collection | 350 | 1 | 10/60 | $28.01 | $1,633.92 |
|  | Incentives Pilot Project Sign Up form – Only for Texas Registrants | 100 | 1 | 3/60 | $28.01 | $140.05 |
| Researchers | ALS Registry Research Application Form | 36 | 1 | 30/60 | $128.68 | $2,316.24 |
| Annual Update | 24 | 1 | 15/60 | $128.68 | $772.08 |
| ALS Service Organizations | Chapter/District Outreach Reporting Form | 135 | 12 | 5/60 | $28.01 | $3,781.35 |
| National Office Outreach Reporting Form | 2 | 12 | 20/60 | $28.01 | $224.08 |
| Total |  |  |  |  |  | $51,601.64 |

# A.13. Estimates of Other Total Annual Cost Burden to Respondents and Record Keepers

There are no capital or maintenance costs incurred by respondents because the information will be entered via the Internet from any location. There are no costs or burden to respondents for recordkeeping.

# A.14. Annualized Cost to the Federal Government

Data analysis by ATSDR may result in action taken by the ATSDR Division of Toxicology and Human Health Studies in response to the required CDC mandate in maintaining preventive health activities and surveillance systems. The action taken will vary, depending on the analysis.

The total cost to the federal government for the collection of this information for the three-year ongoing project is $10,922,466 as itemized below.

Annual ATSDR personnel costs $979,822.

Additional expenses will be incurred by ATSDR in order to operate a successful surveillance program/registry.

* In addition contract staff will contribute to this program: a Senior Scientist (30%), a Program Analyst (100%), Epidemiologist (25%), and Statistician (100%) for a total of $600,000.
* A contractor will be used to maintain the web portal for case registration and participation in surveys in addition to providing public user support 40 hours per week ($651,000).
* ALS service organizations conducting outreach spend approximately 10% of their time meeting reporting requirements ($80,000).
* A contractor will be in charge of the biorepository operations including but not limited to specimen collection, analysis, storage, and distribution of samples $1,310,000.

Lesser expenses may include computer resources, telephone calls, and recruitment materials (approximately $20,000).

The estimated annual cost to the government is $3,640,822.

# A.15. Explanation for Program Changes or Adjustments

This is a nonmaterial/non-substantive change request for the National ALS Registry (OMB Control No. 0923-0041 (expiration date: May 31, 2026).

1. We are requesting OMB approval to update the current consent form to include language for collaboration to federal interagency data exchange between the NIH (ALL ALS) group and the National ALS Registry. Modifications have been Appendix D: Consent Form in track changes and clean. Congress has passed Public Law 117-79, Accelerating Access to Critical Therapies for ALS Act, which tasks the Department of Health and Human Services (HHS) to award grants to eligible entities for scientific research utilizing data from expanded access to investigational ALS treatments for individuals who are not otherwise eligible for clinical trials. The National Institutes of Health (NIH) issued a grant to two institutions, referred to as ALL ALS, to establish a comprehensive network of 34 ALS clinics around the country that will enroll current and newly diagnosed patients in order fulfill this objective. The National ALS Registry, established by Public Law 110-73, ALS Registry Act, tasks the Centers for Disease Control and Prevention (CDC) to determine the epidemiology of ALS as well as the identification of risk factors and possible etiologies. Both of these Congressional mandated programs will allow researchers to better understand and identify mechanisms of disease progression, genetics, and possible treatments. NIH’s ALL ALS will be updating their consent forms to allow the sharing of patient information with the CDC’s National ALS Registry. The sharing of data will be voluntary. The Registry in turn will update their own consent form to share patient data with the NIH. Data sharing will be voluntary. The benefits of data sharing are multifold. First, this will allow the capture of cases from both systems to ensure maximum catchment as well as reduction of duplicative cases and reduce patient burden by enrolling in a single system. This will also reduce overall public burden for the ALS community.
2. Additionally, the National ALS Registry (Registry) is proposing the launch of a pilot incentives project. The Agency for Toxic Substance and Disease Registry (ATSDR) endeavors to improve the completeness, representativeness, and accuracy of the Registry data over time. Enrollment rates for those self-enrolling in the Registry have been lower than expected based on census and prevalence data estimates. Thus, a small incentive will help increase enrollment and participation in the risk factor surveys. The goal of the incentive pilot project will be measured in two parts. The first goal is to increase participation in the Registry. The second goal is to improve risk factor survey completion rates for all 18 surveys. Because the incentive will be provided in two parts, this will incentivize individuals who have registered to also complete risk factor surveys. This pilot will assess the benefits of providing a small monetary incentive on the enrollment and survey completion rates for the Registry. This pilot project proposal, along with the sign-up form is being added as a new appendix (Appendix U and U2 - New).

These changes have been approved by IRB for the protocol for the National ALS Registry. The overall number of respondents and requested burden hours remain the same.

# A.16. Plans for Tabulation and Publication and Project Time Schedule

The National ALS Registry will conduct periodic statistical analyses on the data in the system. An annual registry report will be generated using SAS (SAS Institute, Cary, NC).The annual report will include information from both individuals who self-register and those from administrative data (Medicare, Medicaid, Veterans Health Administration, and Veterans Benefits Administration). Evaluation of the representativeness of those self-registering has been conducted. This information will be part of the annual report. It is anticipated that the annual report will include information on:

* Number of people identified with ALS
* Number of individuals who self-identified vs. those obtained from existing data
* Mean age of case
* Sex distribution of the cases
* Racial distribution of the cases
* Geographic distribution of the cases by region
* Distribution of other characteristics such as cigarette use, alcohol use, occupation, service in the military, physical activity, and family history.

The National ALS Registry coordinator may employ the following methodology:

* Data transformation (e.g. create age categories)
* Case classification

Registry reports will include data both from those individuals identified using existing datasets and those who self-register.

CDC will aggregate the data provided by the registrants on a yearly basis and will publish updated prevalence estimates of ALS in an MMWR Surveillance Summary. In addition, survey data will be analyzed to generate hypotheses for future studies.

Table 3: TIMELINE

|  |  |
| --- | --- |
| **Activity** |  **Time Schedule** |
| Surveillance Activity  | Ongoing data collection |
| Summary Reports  | Every year after OMB approval |
| Yearly Evaluation | Each year after OMB approval |

We also plan to publish selected summary reports on CDC’s public website [www.cdc.gov/als](http://www.cdc.gov/als) .

# A.17. Reason(s) Display of OMB Expiration Date is Inappropriate

Exemption from displaying the expiration date for the OMB approval of forms is not requested.

# A.18. Exceptions to Certification for Paperwork Reduction Act Submissions

There are no exceptions to the certification.

# References

1. Kaye WE, Sanchez M, Wu J. Feasibility of creating a national ALS registry using administrative data in the United States. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:433–9. [http://dx.doi.org/10.3109/2 1678421.2014.887119](http://dx.doi.org/10.3109/2%201678421.2014.887119)
2. Mehta P, Raymond J, Punjani R, et al. Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies, 2017. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2022, DOI: 10.1080/21678421.2022.2059380
3. Mehta P, Raymond J, Punjani R, et al. Incidence of amyotrophic lateral sclerosis in the United States, 2014–2016, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2022, 23:5-6, 378-382, DOI: 10.1080/21678421.2021.2023190
4. Jordan H, Fagliano J, Rechtman L, Lefkowitz D, Kaye W. Population-based surveillance of amyotrophic lateral sclerosis in New Jersey, 2009–2011. Neuroepidemiology 2014;43:49–56. http://dx.doi. org/10.1159/000365850
5. Jordan H, Rechtman L, Wagner L, Kaye WE. Amyotrophic lateral sclerosis surveillance in Baltimore and Philadelphia. Muscle Nerve 2015;51:815–21. <http://dx.doi.org/10.1002/mus.24488>
6. Rechtman L, Wagner L, Kaye W, Villanacci J. Updated Prevalence and Demographic Characteristics for ALS Cases in Texas, 2009–2011. South Med J 2015;108:483–6.
7. Freer C, Hylton T, Jordan HM, Kaye WE, Singh S, Huang Y. Results of Florida’s Amyotrophic Lateral Sclerosis Surveillance Project, 2009–2011. BMJ Open 2015;5:e007359. http://dx.doi.org/10.1136/ bmjopen-2014-007359
8. Valle J, Roberts E, Paulukonis S, Collins N, English P, Kaye W. Epidemiology and surveillance of amyotrophic lateral sclerosis in two large metropolitan areas in California. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:209–15. http://dx.doi.org/10.3109 /21678421.2015.1019516
9. Wagner L, Rechtman L, Jordan H, et al. State and metropolitan area-based amyotrophic lateral sclerosis (ALS) surveillance. Amyotroph Lateral Scler Frontotemporal Degener 2015;17:128–34. [http://dx.doi.org/10. 3109/21678421.2015.1074699](http://dx.doi.org/10.%203109/21678421.2015.1074699)
1. Prior to initiating the Registry, we analyzed approximately 362,000 unique patient records, ATSDR found that using the last four digits of the SSN and last name returned many duplicate matches. Month and year of birth cannot be used for verification because most of the patients fall within a narrow age range and Medicare data are known to contain many inaccuracies in these fields. An additional analysis of the data showed that using the First Initial, Full Last Name and last 5 digits of the SSN returned no duplicate matches for the available file. [↑](#footnote-ref-3)